Cargando…
Benefits of adjuvant treatment including trastuzumab in HER2-positive pT1a-bN0M0 breast cancer: a systematic review and meta-analysis
BACKGROUND: Although trastuzumab has been shown to be beneficial for treating patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, information regarding its benefits is limited to very low-risk cases with tumours ≤1 cm and without lymphatic metastases (pT1abN0). The...
Autores principales: | Lee, Hye Yoon, Shin, In-Soo, Rim, Chai Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154451/ https://www.ncbi.nlm.nih.gov/pubmed/32309334 http://dx.doi.org/10.21037/atm.2020.01.81 |
Ejemplares similares
-
For or against Adjuvant Trastuzumab for pT1a-bN0M0 Breast Cancer Patients with HER2-Positive Tumors: A Meta-Analysis of Published Literatures
por: Zhou, Qiong, et al.
Publicado: (2014) -
Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study
por: Ali, Sanji, et al.
Publicado: (2022) -
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
por: Sasada, Shinsuke, et al.
Publicado: (2023) -
The Effectiveness of Postoperative Chemotherapy on pT1bN0 and pT2N0 Gastric Cancer Patients with Risk Factors: An International Dual-Center Analysis
por: Yang, Kun, et al.
Publicado: (2021) -
HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort
por: Rouanet, Philippe, et al.
Publicado: (2014)